Skip to main content
Canna~Fangled Abstracts

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.

By July 16, 2013No Comments
pm2[Epub ahead of print]

3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.

Source

Université Lille Nord de France, EA4481, Institut de Chimie Pharmaceutique Albert Lespagnol, IFR114, 3 Rue du Pr. Laguesse, BP83, F-59006 Lille, France.

Abstract

Recent investigations showed that anandamide, the main endogenous ligand of CB1 and CB2 cannabinoid receptors, possesses analgesic, antidepressant and anti-inflammatory effects. In the perspective to treat inflammatory bowel disease (IBD), our approach was to develop new selective CB2 receptor agonists without psychotropic side effects associated to CB1 receptors. In this purpose, a new series of 3-carboxamido-5-aryl-isoxazoles, never described previously as CB2 receptor agonists, was designed, synthesized and evaluated for their biological activity. The pharmacological results have identified great selective CB2 agonists with in vivo anti-inflammatory activity in a DSS-induced acute colitis mouse model.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Icon for Elsevier Science

Graphical abstract

Full-size image (17 K)

Keywords

  • CB2;
  • Cannabinoid;
  • Isoxazoles;
  • IBD
Corresponding author contact information
Corresponding author. Tel.: +33 3 20 96 49 06; fax: +33 3 20 96 43 74.

Copyright © 2013 Elsevier Ltd. All rights reserved.
potp font 1